TY  - JOUR
AU  - Xochelli, Aliki
AU  - Baliakas, Panagiotis
AU  - Kavakiotis, Ioannis
AU  - Agathangelidis, Andreas
AU  - Sutton, Lesley-Ann
AU  - Minga, Eva
AU  - Ntoufa, Stavroula
AU  - Tausch, Eugen
AU  - Yan, Xiao-Jie
AU  - Shanafelt, Tait
AU  - Plevova, Karla
AU  - Boudjogra, Myriam
AU  - Rossi, Davide
AU  - Davis, Zadie
AU  - Navarro, Alba
AU  - Sandberg, Yorick
AU  - Vojdeman, Fie Juhl
AU  - Scarfo, Lydia
AU  - Stavroyianni, Niki
AU  - Sudarikov, Andrey
AU  - Veronese, Silvio
AU  - Tzenou, Tatiana
AU  - Karan-Đurašević, Teodora
AU  - Catherwood, Mark
AU  - Kienle, Dirk
AU  - Chatzouli, Maria
AU  - Facco, Monica
AU  - Bahlo, Jasmin
AU  - Pott, Christiane
AU  - Pedersen, Lone Bredo
AU  - Mansouri, Larry
AU  - Smedby, Karin E.
AU  - Chu, Charles C.
AU  - Giudicelli, Veronique
AU  - Lefranc, Marie-Paule
AU  - Panagiotidis, Panagiotis
AU  - Juliusson, Gunnar
AU  - Anagnostopoulos, Achilles
AU  - Vlahavas, Ioannis
AU  - Antić, Darko
AU  - Trentin, Livio
AU  - Montillo, Marco
AU  - Niemann, Carsten
AU  - Doehner, Hartmut
AU  - Langerak, Anton W.
AU  - Pospisilova, Sarka
AU  - Hallek, Michael
AU  - Campo, Elias
AU  - Chiorazzi, Nicholas
AU  - Maglaveras, Nikos
AU  - Oscier, David
AU  - Gaidano, Gianluca
AU  - Jelinek, Diane F.
AU  - Stilgenbauer, Stephan
AU  - Chouvarda, Ioanna
AU  - Darzentas, Nikos
AU  - Belessi, Chrysoula
AU  - Davi, Frederic
AU  - Hadzidimitriou, Anastasia
AU  - Rosenquist, Richard
AU  - Ghia, Paolo
AU  - Stamatopoulos, Kostas
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1611
AB  - Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P  lt  0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management.
PB  - Amer Assoc Cancer Research, Philadelphia
T2  - Clinical Cancer Research
T1  - Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
EP  - 5301
IS  - 17
SP  - 5292
VL  - 23
DO  - 10.1158/1078-0432.CCR-16-3100
ER  - 

@article{
author = "Xochelli, Aliki and Baliakas, Panagiotis and Kavakiotis, Ioannis and Agathangelidis, Andreas and Sutton, Lesley-Ann and Minga, Eva and Ntoufa, Stavroula and Tausch, Eugen and Yan, Xiao-Jie and Shanafelt, Tait and Plevova, Karla and Boudjogra, Myriam and Rossi, Davide and Davis, Zadie and Navarro, Alba and Sandberg, Yorick and Vojdeman, Fie Juhl and Scarfo, Lydia and Stavroyianni, Niki and Sudarikov, Andrey and Veronese, Silvio and Tzenou, Tatiana and Karan-Đurašević, Teodora and Catherwood, Mark and Kienle, Dirk and Chatzouli, Maria and Facco, Monica and Bahlo, Jasmin and Pott, Christiane and Pedersen, Lone Bredo and Mansouri, Larry and Smedby, Karin E. and Chu, Charles C. and Giudicelli, Veronique and Lefranc, Marie-Paule and Panagiotidis, Panagiotis and Juliusson, Gunnar and Anagnostopoulos, Achilles and Vlahavas, Ioannis and Antić, Darko and Trentin, Livio and Montillo, Marco and Niemann, Carsten and Doehner, Hartmut and Langerak, Anton W. and Pospisilova, Sarka and Hallek, Michael and Campo, Elias and Chiorazzi, Nicholas and Maglaveras, Nikos and Oscier, David and Gaidano, Gianluca and Jelinek, Diane F. and Stilgenbauer, Stephan and Chouvarda, Ioanna and Darzentas, Nikos and Belessi, Chrysoula and Davi, Frederic and Hadzidimitriou, Anastasia and Rosenquist, Richard and Ghia, Paolo and Stamatopoulos, Kostas",
year = "2017",
abstract = "Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P  lt  0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management.",
publisher = "Amer Assoc Cancer Research, Philadelphia",
journal = "Clinical Cancer Research",
title = "Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes",
pages = "5301-5292",
number = "17",
volume = "23",
doi = "10.1158/1078-0432.CCR-16-3100"
}

Xochelli, A., Baliakas, P., Kavakiotis, I., Agathangelidis, A., Sutton, L., Minga, E., Ntoufa, S., Tausch, E., Yan, X., Shanafelt, T., Plevova, K., Boudjogra, M., Rossi, D., Davis, Z., Navarro, A., Sandberg, Y., Vojdeman, F. J., Scarfo, L., Stavroyianni, N., Sudarikov, A., Veronese, S., Tzenou, T., Karan-Đurašević, T., Catherwood, M., Kienle, D., Chatzouli, M., Facco, M., Bahlo, J., Pott, C., Pedersen, L. B., Mansouri, L., Smedby, K. E., Chu, C. C., Giudicelli, V., Lefranc, M., Panagiotidis, P., Juliusson, G., Anagnostopoulos, A., Vlahavas, I., Antić, D., Trentin, L., Montillo, M., Niemann, C., Doehner, H., Langerak, A. W., Pospisilova, S., Hallek, M., Campo, E., Chiorazzi, N., Maglaveras, N., Oscier, D., Gaidano, G., Jelinek, D. F., Stilgenbauer, S., Chouvarda, I., Darzentas, N., Belessi, C., Davi, F., Hadzidimitriou, A., Rosenquist, R., Ghia, P.,& Stamatopoulos, K.. (2017). Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. in Clinical Cancer Research
Amer Assoc Cancer Research, Philadelphia., 23(17), 5292-5301.
https://doi.org/10.1158/1078-0432.CCR-16-3100

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton L, Minga E, Ntoufa S, Tausch E, Yan X, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Đurašević T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc M, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antić D, Trentin L, Montillo M, Niemann C, Doehner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. in Clinical Cancer Research. 2017;23(17):5292-5301.
doi:10.1158/1078-0432.CCR-16-3100 .

Xochelli, Aliki, Baliakas, Panagiotis, Kavakiotis, Ioannis, Agathangelidis, Andreas, Sutton, Lesley-Ann, Minga, Eva, Ntoufa, Stavroula, Tausch, Eugen, Yan, Xiao-Jie, Shanafelt, Tait, Plevova, Karla, Boudjogra, Myriam, Rossi, Davide, Davis, Zadie, Navarro, Alba, Sandberg, Yorick, Vojdeman, Fie Juhl, Scarfo, Lydia, Stavroyianni, Niki, Sudarikov, Andrey, Veronese, Silvio, Tzenou, Tatiana, Karan-Đurašević, Teodora, Catherwood, Mark, Kienle, Dirk, Chatzouli, Maria, Facco, Monica, Bahlo, Jasmin, Pott, Christiane, Pedersen, Lone Bredo, Mansouri, Larry, Smedby, Karin E., Chu, Charles C., Giudicelli, Veronique, Lefranc, Marie-Paule, Panagiotidis, Panagiotis, Juliusson, Gunnar, Anagnostopoulos, Achilles, Vlahavas, Ioannis, Antić, Darko, Trentin, Livio, Montillo, Marco, Niemann, Carsten, Doehner, Hartmut, Langerak, Anton W., Pospisilova, Sarka, Hallek, Michael, Campo, Elias, Chiorazzi, Nicholas, Maglaveras, Nikos, Oscier, David, Gaidano, Gianluca, Jelinek, Diane F., Stilgenbauer, Stephan, Chouvarda, Ioanna, Darzentas, Nikos, Belessi, Chrysoula, Davi, Frederic, Hadzidimitriou, Anastasia, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas, "Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes" in Clinical Cancer Research, 23, no. 17 (2017):5292-5301,
https://doi.org/10.1158/1078-0432.CCR-16-3100 . .

TY  - JOUR
AU  - Xochelli, Aliki
AU  - Baliakas, Panagiotis
AU  - Kavakiotis, Ioannis
AU  - Agathangelidis, Andreas
AU  - Sutton, Lesley-Ann
AU  - Minga, Eva
AU  - Ntoufa, Stavroula
AU  - Tausch, Eugen
AU  - Yan, Xiao-Jie
AU  - Shanafelt, Tait
AU  - Plevova, Karla
AU  - Boudjogra, Myriam
AU  - Rossi, Davide
AU  - Davis, Zadie
AU  - Navarro, Alba
AU  - Sandberg, Yorick
AU  - Vojdeman, Fie Juhl
AU  - Scarfo, Lydia
AU  - Stavroyianni, Niki
AU  - Sudarikov, Andrey
AU  - Veronese, Silvio
AU  - Tzenou, Tatiana
AU  - Karan-Đurašević, Teodora
AU  - Catherwood, Mark
AU  - Kienle, Dirk
AU  - Chatzouli, Maria
AU  - Facco, Monica
AU  - Bahlo, Jasmin
AU  - Pott, Christiane
AU  - Pedersen, Lone Bredo
AU  - Mansouri, Larry
AU  - Smedby, Karin E.
AU  - Chu, Charles C.
AU  - Giudicelli, Veronique
AU  - Lefranc, Marie-Paule
AU  - Panagiotidis, Panagiotis
AU  - Juliusson, Gunnar
AU  - Anagnostopoulos, Achilles
AU  - Vlahavas, Ioannis
AU  - Antić, Darko
AU  - Trentin, Livio
AU  - Montillo, Marco
AU  - Niemann, Carsten
AU  - Doehner, Hartmut
AU  - Langerak, Anton W.
AU  - Pospisilova, Sarka
AU  - Hallek, Michael
AU  - Campo, Elias
AU  - Chiorazzi, Nicholas
AU  - Maglaveras, Nikos
AU  - Oscier, David
AU  - Gaidano, Gianluca
AU  - Jelinek, Diane F.
AU  - Stilgenbauer, Stephan
AU  - Chouvarda, Ioanna
AU  - Darzentas, Nikos
AU  - Belessi, Chrysoula
AU  - Davi, Frederic
AU  - Hadzidimitriou, Anastasia
AU  - Rosenquist, Richard
AU  - Ghia, Paolo
AU  - Stamatopoulos, Kostas
PY  - 2017
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1017
AB  - Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P  lt  0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management.
PB  - Amer Assoc Cancer Research, Philadelphia
T2  - Clinical Cancer Research
T1  - Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
EP  - 5301
IS  - 17
SP  - 5292
VL  - 23
DO  - 10.1158/1078-0432.CCR-16-3100
ER  - 

@article{
author = "Xochelli, Aliki and Baliakas, Panagiotis and Kavakiotis, Ioannis and Agathangelidis, Andreas and Sutton, Lesley-Ann and Minga, Eva and Ntoufa, Stavroula and Tausch, Eugen and Yan, Xiao-Jie and Shanafelt, Tait and Plevova, Karla and Boudjogra, Myriam and Rossi, Davide and Davis, Zadie and Navarro, Alba and Sandberg, Yorick and Vojdeman, Fie Juhl and Scarfo, Lydia and Stavroyianni, Niki and Sudarikov, Andrey and Veronese, Silvio and Tzenou, Tatiana and Karan-Đurašević, Teodora and Catherwood, Mark and Kienle, Dirk and Chatzouli, Maria and Facco, Monica and Bahlo, Jasmin and Pott, Christiane and Pedersen, Lone Bredo and Mansouri, Larry and Smedby, Karin E. and Chu, Charles C. and Giudicelli, Veronique and Lefranc, Marie-Paule and Panagiotidis, Panagiotis and Juliusson, Gunnar and Anagnostopoulos, Achilles and Vlahavas, Ioannis and Antić, Darko and Trentin, Livio and Montillo, Marco and Niemann, Carsten and Doehner, Hartmut and Langerak, Anton W. and Pospisilova, Sarka and Hallek, Michael and Campo, Elias and Chiorazzi, Nicholas and Maglaveras, Nikos and Oscier, David and Gaidano, Gianluca and Jelinek, Diane F. and Stilgenbauer, Stephan and Chouvarda, Ioanna and Darzentas, Nikos and Belessi, Chrysoula and Davi, Frederic and Hadzidimitriou, Anastasia and Rosenquist, Richard and Ghia, Paolo and Stamatopoulos, Kostas",
year = "2017",
abstract = "Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P  lt  0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management.",
publisher = "Amer Assoc Cancer Research, Philadelphia",
journal = "Clinical Cancer Research",
title = "Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes",
pages = "5301-5292",
number = "17",
volume = "23",
doi = "10.1158/1078-0432.CCR-16-3100"
}

Xochelli, A., Baliakas, P., Kavakiotis, I., Agathangelidis, A., Sutton, L., Minga, E., Ntoufa, S., Tausch, E., Yan, X., Shanafelt, T., Plevova, K., Boudjogra, M., Rossi, D., Davis, Z., Navarro, A., Sandberg, Y., Vojdeman, F. J., Scarfo, L., Stavroyianni, N., Sudarikov, A., Veronese, S., Tzenou, T., Karan-Đurašević, T., Catherwood, M., Kienle, D., Chatzouli, M., Facco, M., Bahlo, J., Pott, C., Pedersen, L. B., Mansouri, L., Smedby, K. E., Chu, C. C., Giudicelli, V., Lefranc, M., Panagiotidis, P., Juliusson, G., Anagnostopoulos, A., Vlahavas, I., Antić, D., Trentin, L., Montillo, M., Niemann, C., Doehner, H., Langerak, A. W., Pospisilova, S., Hallek, M., Campo, E., Chiorazzi, N., Maglaveras, N., Oscier, D., Gaidano, G., Jelinek, D. F., Stilgenbauer, S., Chouvarda, I., Darzentas, N., Belessi, C., Davi, F., Hadzidimitriou, A., Rosenquist, R., Ghia, P.,& Stamatopoulos, K.. (2017). Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. in Clinical Cancer Research
Amer Assoc Cancer Research, Philadelphia., 23(17), 5292-5301.
https://doi.org/10.1158/1078-0432.CCR-16-3100

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton L, Minga E, Ntoufa S, Tausch E, Yan X, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Đurašević T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc M, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antić D, Trentin L, Montillo M, Niemann C, Doehner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. in Clinical Cancer Research. 2017;23(17):5292-5301.
doi:10.1158/1078-0432.CCR-16-3100 .

Xochelli, Aliki, Baliakas, Panagiotis, Kavakiotis, Ioannis, Agathangelidis, Andreas, Sutton, Lesley-Ann, Minga, Eva, Ntoufa, Stavroula, Tausch, Eugen, Yan, Xiao-Jie, Shanafelt, Tait, Plevova, Karla, Boudjogra, Myriam, Rossi, Davide, Davis, Zadie, Navarro, Alba, Sandberg, Yorick, Vojdeman, Fie Juhl, Scarfo, Lydia, Stavroyianni, Niki, Sudarikov, Andrey, Veronese, Silvio, Tzenou, Tatiana, Karan-Đurašević, Teodora, Catherwood, Mark, Kienle, Dirk, Chatzouli, Maria, Facco, Monica, Bahlo, Jasmin, Pott, Christiane, Pedersen, Lone Bredo, Mansouri, Larry, Smedby, Karin E., Chu, Charles C., Giudicelli, Veronique, Lefranc, Marie-Paule, Panagiotidis, Panagiotis, Juliusson, Gunnar, Anagnostopoulos, Achilles, Vlahavas, Ioannis, Antić, Darko, Trentin, Livio, Montillo, Marco, Niemann, Carsten, Doehner, Hartmut, Langerak, Anton W., Pospisilova, Sarka, Hallek, Michael, Campo, Elias, Chiorazzi, Nicholas, Maglaveras, Nikos, Oscier, David, Gaidano, Gianluca, Jelinek, Diane F., Stilgenbauer, Stephan, Chouvarda, Ioanna, Darzentas, Nikos, Belessi, Chrysoula, Davi, Frederic, Hadzidimitriou, Anastasia, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas, "Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes" in Clinical Cancer Research, 23, no. 17 (2017):5292-5301,
https://doi.org/10.1158/1078-0432.CCR-16-3100 . .